North America Alopecia Market Insights Forecasts to 2032

• The North America Alopecia Market Size was valued at USD 2.88 Billion in 2022.
• The Market Size is Growing at a CAGR of 8.1% from 2022 to 2032
• The North America Alopecia Market Size is expected to reach USD 6.28 Billion by 2032.

The North America Alopecia Market Size is expected To Grow to USD 6.28 Billion by 2032, at a CAGR of 8.1% during the forecast period 2022-2032.

Market Overview

Alopecia is a medical disorder characterized by rapid, severe hair loss on the scalp, typically in circular regions. Alopecia areata, for example, is a common autoimmune illness that causes baldness and partial or full hair loss. In addition, the market is likely to be driven by technical advances in therapies as well as an increase in the frequency of disorders linked with hair loss. Furthermore, many strategic efforts made by major companies, such as the development of light-based therapy and other pharmaceutical product advancements, are expected to drive growth throughout the forecast period. Moreover, continuing funding efforts by prominent organizations to close research gaps in hair diseases are projected to accelerate market development. For instance, the American Academy of Dermatology Association, announced the start of the Hair Loss and Alopecia Initiative in Research (HAIR) funding initiative in April 2021. This HAIR initiative will provide money to researchers, trainees, and dermatologists in the United States for the completion of research projects aimed at developing innovative remedies for hair diseases.

Report Coverage

This research report categorizes the market of North America alopecia market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America alopecia market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the North America alopecia market.

Driving Factors

The primary drivers driving the market include the increased incidence of alopecia, as well as the rising prevalence of autoimmune and other chronic illnesses that cause hair loss. Hair loss affects around 80 million Americans, with 30 million women and 50 million men affected, according to the American Academy of Dermatology Association. Furthermore, it is estimated that 10% to 20% of patients with alopecia areata have a close blood family who already has the disease. Furthermore, the presence of numerous major competitors in the area, as well as the launch of innovative therapy alternatives, are projected to boost the North America alopecia market. Product line growth by market leaders drives the market.

Market Segment

• In 2022, the pharmaceuticals segment is influencing the largest market share over the forecast period.

Based on the disease type, the North America alopecia market is segmented into pharmaceuticals, oral, and devices. Among these segments, the pharmaceuticals segment dominates the largest market share during the forecast period due to increased demand for medications to cure hair loss, decreasing pharmaceutical product costs, simple availability, and numerous efforts made by pharmaceutical companies to create innovative treatments for alopecia.

• In 2022, the alopecia areata segment is dominating the largest market share during the forecast period.

Based on the treatment, the North America alopecia market is segmented into alopecia areata, cicatricial alopecia, traction alopecia, alopecia totalis, alopecia universalis, & androgenetic alopecia. Among these segments, the alopecia areata segment dominates the largest market share during the forecast period due to rising disease prevalence, high treatment rates, increased awareness of alopecia areata, and different ongoing regulatory approvals. According to the NAAF, more than 6.8 million persons in the United States have alopecia areata, with a lifetime risk of 2.1%. Furthermore, continued regulatory approvals are projected to drive segment expansion.

• In 2022, the dermatology clinics segment is leading the largest market share during the forecast period.

 Based on the end user, the North America alopecia market is segmented into homecare settings and dermatology clinics. Among these segments, the dermatology clinics segment dominates the largest market share during the forecast period owing to the increasing focus on aesthetic appearance, greater consciousness about appearance, and improved consumer knowledge regarding hair loss management and therapy are driving demand for dermatological clinics.

• In 2022, the prescriptions segment is dominating the largest market share during the forecast period.

Based on the sales channel, the North America alopecia market is segmented into prescriptions and OTC. Among these segments, the prescriptions segment dominates the largest market share during the forecast period due to increasing instances of severe alopecia areata, more outpatient visits for alopecia areata therapy, and the existence of a rich pipeline of experimental candidates for hair loss management.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America alopecia market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Cipla Inc.
• Sun Pharmaceuticals Industries Ltd
• Johnson & Johnson Services, Inc
• Merck & Co., Inc.
• Lexington Intl., LLC
• Cirrus Hair Centers
• Vita-Cos-Med Klett-Loch GmbH
• Transitions Hair
• PureTech Health
• Curallux, LLC
• Dr. Reddy's Laboratories Ltd
• GSK plc
• Aurobindo Pharma
• Mylan N.V. (Viatris, Inc.)
• Freedom Laser Therapy, Inc.
• Apira Science, Inc. (iGrow Laser.)
• Revian, Inc
• Theradome
• LUTRONIC
• WON TECH Co., Ltd
• LifeMD
• LG Electronics

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In June 2022, Incyte and Eli Lilly and Company announced that OLUMIANT (baricitinib) has been approved by the US Food and Drug Administration for systemic treatment of people with severe AA. OLUMIANT tablet strengths include 1 mg, 2 mg, and 4 mg.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the North America Alopecia Market based on the below-mentioned segments:

North America Alopecia Market, By Treatment

• Pharmaceuticals

• Oral
• Devices

North America Alopecia Market, By Disease Type

• Alopecia Areata

• Cicatricial Alopecia
• Traction Alopecia
• Alopecia Totalis
• Alopecia Universalis
• Androgenetic Alopecia

North America Alopecia Market, By End User

• Homecare Settings
• Dermatology Clinics

North America Alopecia Market, By Sales Channel

• Prescriptions
• OTC